Thrombotic complications in children with haematologic malignacies

Thrombosis Research

Volumn 125, Issue , 2010, Pages S151-S154

  Putti, Maria Caterina ^a   Randi, Maria Luigia ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Acute leukemia; Children; Essential Thrombocytosis; Polycythemia Vera; Thrombosis

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; HUMAN; LEUKEMIA; LYMPHOMA; THROMBOSIS;

CHILD; HUMANS; LEUKEMIA; LYMPHOMA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; THROMBOSIS;

EID: 77955487712     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(10)70034-7     Document Type: Article

References (60)

1. Van Ommen, CH, Heijboer, H, Buller, HR, Hijrasing, RA, Heijmans, HS, Peters, M, Venous thromboembolism in childhood: a propsective two year registry in the Netherlands. J Ped 139 (2001), 676–681.
2. Monagle, P, Adams, M, Mahoney, M, Ali, K, Barnard, D, Bernstein, M, et al. Outcome of the pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 47 (2000), 763–766.
3. Young, G, Albisetti, M, Bonduel, M, Brandao, L, Chan, A, Friedrichs, F, et al. Impact of inherited thrombophilia on venous thromboembolism in children. A systematic review and meta-analysis of observational studies. Circulation 118 (2008), 1373–1382.
4. Prandoni, P, Trujillo-Santos, J, Surico, T, Dalla Valle, F, Piccioli, A, Monreal, M, Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry. Haematologica 93 (2008), 1432–1434.
5. Payne, JHH, Vora, AJ, Thrombosis and acute lymphoblastic leukemia. Br J Haematol 138 (2007), 430–445.
6. Landolfi, R, Di Gennaro, L, Falanga, A, Thrombosis in myeloproliferative disorders: pathogenetic facts and speculations. Leukemia 22 (2008), 2020–2028.
7. Neegard, HFS, Iversen, PO, Ostenstad, B, Iversen, N, Holme, PA, Sandset, PM, Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor. Thromb Haemost 99 (2008), 1040–1048.
8. Testi, AM, Biondi, A, Lo Coco, F, Moleti, ML, Giona, F, Vignetti, M, et al. GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 106 (2005), 447–453.
9. Athale, U, Cox, S, Siciliano, S, Chan, AKC, Thromboembolism in children with sarcoma. Pediatr Blood Cancer 49 (2007), 171–176.
10. Ruud, E, Holmstrom, H, Natvig, S, Wesenberg, F, Prevalence of thrombophilia and central venous catheter associated-neck vein thrombosis in 41 children with cancer. A prospective study. Med Pediatr Oncol 38 (2002), 405–410.
11. Athale, U, Sicilian, S, Thabane, L, Pai, N, Cox, S, Lathia, A, et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 51 (2008), 792–797.
12. Nowak-Goettl, U, Ahlke, E, Fleischhak, G, Schwabe, D, Schoebess, R, Schumann, C, et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols). Prednisone versus dexametasone administration. Blood 101 (2003), 2529–2533.
13. Nowak-Goettl, U, Kennet, G, Mitchell, LG, Thrombosis in childhood acute lymphoblastic leukemia: epidemiology, aetiology, diagnosis, and treatment. Best Pract Res Clin Haematol 22 (2009), 103–114.
14. Caruso, V, Iacoviello, L, Di Castelnuovo, AD, Storti, S, Mariani, G, De Gaetano, G, et al. Thrombotic complication in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 patients. Blood 108 (2006), 2216–2222.
15. Giordano, P, Santoro, N, Del Vecchio, GC, Rizzari, C, Masera, G, De Mattia, D, T-immunophenotype is associated with an increased prevalence of thrombosis in children with acute lymphoblastic leukemia. A retrospective study. Haematologica 88 (2003), 1079–1080.
16. Athale, U, Chan, AKC, Thrombosis in children with acute lymphoblastic leukemia, Part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thrombosis Research 111 (2003), 125–131.
17. Athale, U, Chan, AKC, Thrombosis in children with acute lymphoblastic leukemia, Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thrombosis research 111 (2003), 199–212.
18. Athale, U, Chan, AKC, Thrombosis in children with acute lymphoblastic leukemia, Part III. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of host environment. Thrombosis research 111 (2003), 321–327.
19. Mitchell, L, the PAARKA Group. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase. (PAARKA Study). Cancer 97 (2003), 508–516.
20. Ruud, E, Holstrom, H, De Lange, C, Natvig, S, Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL 1992 vs NOPHO ALL 2000): a single institution study. Pediatr Haematol Oncol 23 (2006), 207–216.
21. Nowak Goettl, U, Heinecke, A, Von Kries, R, Nurnberger, W, Munchow, N, Junker, R, Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant E Coli asparaginase/prednisone administration. Thromb Res 103 (2001), 165–172.
22. Meister, B, Kropshoefer, G, Kelin-Franke, A, Strasak, AM, Hager, J, Streif, W, Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 50 (2008), 298–303.
23. Sartori, MT, Spiezia, L, Cesaro, S, Messina, C, Paris, M, Pillon, M, et al. Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population. Thromb Haemost 93 (2005), 682–689.
24. Horowitz, N, Brenner, B, Thrombophilia and cancer. Pathophisiol Haemost Thromb 36 (2007), 131–136.
25. O'Brien, SH, Smith, KJ, Using Thrombophilia Testing to Determine Anticoagulation Duration in Pediatric Thrombosis is not Cost-Effective. J Ped 155 (2009), 100–104.
26. Mazzoleni, S, Putti, MC, Simioni, P, Sainati, L, Tormene, D, Manara, R, et al. Early cerebral sinovenous thrombosis in a child with acute lymphoblastic leukemia carrying the prothrombin G20210A variant: a case report and review of the literature. Blood Coagul Fibrinol 16 (2005), 43–49.
27. Stiakaki, E, Germanakis, I, Sfyridaki, C, Katzilakis, N, Danilatou, V, Kalmanti, M, Prevalence of Factor V Leiden and other thrombophilic traits among Cretan children with malignancy. Pediatr Blood Cancer 44 (2005), 386–389.
28. Kuhle, S, Spavor, M, Massicotte P Halton, J, Cherrick, I, Dix, D, et al. Prevalence of post-thrombotic syndrome following asymptomatic thrombosis in survivors of acute lymphoblastic leukemia. J Thromb Haemost 6 (2008), 589–594.
29. Sebire, G, Tabarki, B, Sauders, E, Leroy, R, Saint-Martin, C, Husson, B, et al. Cerebral venous sinus thrombosis in children: risk factor, presentation, diagnosis and outcome. Brain 128 (2005), 477–489.
30. Santoro, N, Giordano, P, Del Vecchio, GC, Guido, G, Rizzari, C, Varotto, S, et al. Ischemic stroke in children treated for acute lymphoblastic leukemia: a retrospective study. J Pediatr Hematol Oncol 27 (2005), 153–157.
31. Demopoulos, A, De Angelis, LM, Neurologic complications of leukemia. Curr Opin Neurol 15 (2002), 691–699.
32. Cesaro, S, Tridello, G, Cavaliere, M, Magagna, L, Gavin, P, Cusinato, R, et al. Prospective, randomized trial of two different modalities of flushing central venous catheters in pediatric patients with cancer. J Clin Oncol 27 (2009), 2059–2065.
33. Fratino, G, Avanzini, S, Molinari, AC, Buffa, P, Castagnola, E, Haupt, R, Incidence of indwelling central catheter-related complications using the Sri Paran technique for device fixation in children with cancer. Pediatr Surg Int 25 (2009), 591–594.
34. Randi, ML, Putti, MC, Pediatric Myeloproliferative neoplasms. Haematology Education; EHA, Berlin 3 (2009), 50–55.
35. Teofili, L, Giona, F, Marini, M, Cenci, T, Guidi, F, Torti, L, et al. Markers of myeloproliferative diseases in childhood with polycythemia vera and essential thrombocythemia. J Clin Oncol 26 (2007), 1048–1053.
36. Cario, H, Schwartz, K, Herter, JM, Komrska, V, Mb Mullin, MF, Minkov, M, et al. Br J Haematol 142 (2008), 622–626.
37. Kralovics, R, Passamonti, F, Buser, AS, Teo, SS, Tiedt, R, Passweg, JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005), 1779–1790.
38. Baxter, EJ, Scott, LM, Campbell, PJ, East, C, Fourouclas, N, Swanton, S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005), 1054–1061.
39. Tefferi, A, Vardiman, JW, Classification and diagnosis of myeloproliferative neoplasm: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22 (2008), 14–22.
40. Teofili, L, Giona, F, Martini, M, Cenci, T, Guidi, F, Torti, L, et al. The revised WHO criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 110 (2007), 3384–3386.
41. Teofili, L, Foá, R, Giona, F, Larocca, LM, Childhood polycythemia vera and essential thrombocythemia does their pathogenesis overlap with that of adults. Haematologica 93 (2008), 169–172.
42. Randi, ML, Putti, MC, Scapin, M, Pacquola, E, Tucci, F, Micalizzi, C, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 108 (2006), 3600–3602.
43. Finazzi, G, Barbui, T, Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 22 (2008), 1494–1502.
44. Barbui, T, Barosi, G, Grossi, A, Gugliotta, L, Liberato, LN, Marchetti, M., et al. Practice guidelines fro the therapy of essential thrombocytemia. A statement from the Italian Society of Hematology, the Italian Experimental Haematology and the Italian group fro Bone Marrow transplantation. Haematologica 89 (2004), 215–232.
45. Barbui, T, Finazzi, G, Therapy for polycythemia vera and essential throm-bocythemia is driven by the cardiovascular risk. Semin Thromb Hemost 33 (2007), 321–329.
46. Carobbio, A, Finazzi, G, Guerrini, V, Spinelli, O, Delaini, E, Marchioli, R, et al. Leucocytosis and risk stratification for thrombosis in essential thrombocythemia: interaction with treatment, standard risk stratification and JAK2 mutation assessment in essential thrombocythemia. J Clin Oncol 26 (2008), 2732–3273.
47. Dame, C, Sutor, AH, Primary and secondary thrombocytosis in childhood. Br J Haematol 129 (2005), 165–177.
48. Putti, MC, Giona, F, Consarino, C, Fiori, GM, Giordano, P, Ladogana, S, et al. Retrospective evaluation of 90 children with essential thrombocythemia: the AIEOP experience. Blood (ASH abs), 112, 2008, 664.
49. Campbell, PJ, Scott, LM, Buck, G, Wheatley, K, East, CL, Marsden, JT, et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 (2005), 1945–1953.
50. Falanga, A, Marchetti, M, Vignoli, A, Balducci, D, Russo, L, Guerini, V, et al. V617F JAK2 mutation in patients with essential thrombocytemia: relation to platelet, granulocyte and plasma hemostatic and inflammatory molecules. Exp Hematol 35 (2007), 702–711.
51. Teofili, L, Cenci, T, Martini, M, Capodimonti, S, Torti, L, Giona, F, et al. The mutant JAK2 allele burden in children with essential thrombocythemia. Br J Haematol 145 (2009), 430–432.
52. Kiladjian, JJ, Cervantes, F, Leebeck, FW, Marzac, C, Cassinat, B, Chevret, S, et al. The impact of JAK2V617 F and MPL mutation on diagnosis and prognosis of splancnic vein thrombosis. Blood 111 (2008), 4922–4929.
53. Falanga, A, Barbui, T, Rickles, FR, Hypercoagulability and tissue factor gene upregulation in haematologic malignancies. Semin Thromb Hemost 34 (2008), 204–210.
54. Cario, H, Childhood polycythemias/erythrocytoses: classification, diagnosis, clinical presentation and treatment. Ann Hematol 84 (2005), 137–145.
55. Prchal, JT, Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders. Semin Hematol 36 (2001), 10–20.
56. Teofili, L, Giona, F, Torti, L, Cenci, T, Ricerca, BM, Rumi, C, et al. MPLSer505Asn induced hereditary thrombocytosis is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica, 2009 E-pub.
57. Landolfi, R, Marchioli, R, Kutti, J, Gisslinger, H, Tognoni, G, Patrono, C, et al. Efficacy and safety of low dose aspirin in polycythemia vera. N Engl J Med 350 (2004), 114–124.
58. Randi, ML, Putti, MC, Essential thrombocythemia in children: is a treatment needed?. Expert Opin Pharmacoter 5 (2004), 1009–1014.
59. Monagle, P, Chalmers, E, Chan, A, DeVeber, G, Kirkham, F, Massicotte, P, et al. Antithrombotic therapy in neonates and children. Chest 133 (2008), 887–968.
60. Giordano, P, Del Vecchio, GC, Saracco, P, Zecca, M, Molinari, AC, De Mattia, D, A practical approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute lymphoblastic leukemia: recommendation of the “Coagulation Defects” AIEOP Working Group. Recent Pat Cardiovasc Drug Discov 2 (2007), 53–62.